Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Osteogenic sarcoma: the past, present, and future.

M M Copeland, W W Sutow

    International Advances in Surgical Oncology
    |January 1, 1979
    PubMed
    Summary
    This summary is machine-generated.

    Related Concept Videos

    You might also read

    Related Articles

    Articles linked to this work by shared authors, journal, and citation graph.

    Sort by
    Same author

    Bone diseases with osteoporotic or malacic changes.

    The Southern surgeon·2014
    Same author

    Medical survey of Rongelap people eight years after exposure to fallout.

    T. Brookhaven National Laboratory·2014
    Same author

    Newer aspects of benign tumors of the breast.

    Archives of surgery (Chicago, Ill. : 1920)·2010
    Same author

    Chemotherapy-induced histologic changes in Wilms' tumors.

    Pediatric pathology·1984
    Same author

    Renal cell carcinoma in children.

    Medical and pediatric oncology·1983
    Same author

    [Experimental study on pharmacokinetics of methotrexate and its metabolite (7-hydroxy-methotrexate) in tissue].

    Gan to kagaku ryoho. Cancer & chemotherapy·1982
    Same journal

    Adjuvant therapy for carcinoma of the colon and rectum.

    International advances in surgical oncology·1984
    Same journal

    Pancreatic cancer.

    International advances in surgical oncology·1984
    Same journal

    Surgical treatment of thyroid cancer.

    International advances in surgical oncology·1984
    Same journal

    Advances in the treatment of testicular tumors.

    International advances in surgical oncology·1984
    Same journal

    Malignant esophageal tumors concomitant with benign esophageal diseases.

    International advances in surgical oncology·1984
    Same journal

    Vitamin A and retinoids: a hypothesis of tumour chemoprevention.

    International advances in surgical oncology·1984
    See all related articles

    Osteogenic sarcoma (osteosarcoma) treatment has advanced with adjuvant chemotherapy, improving survival rates, especially in nonmetastatic cases. However, long-term cure remains uncertain due to potential disease recurrence.

    Area of Science:

    • Oncology
    • Orthopedic Surgery
    • Medical Research

    Background:

    • Osteogenic sarcoma (osteosarcoma) is a malignant bone-forming tumor with variable histology and prognosis.
    • Prognostic factors include tumor histology, site, symptom duration, and disease extent.
    • Traditional treatments like amputation are being enhanced by newer therapeutic strategies.

    Purpose of the Study:

    • To review current treatment modalities for osteogenic sarcoma.
    • To highlight advances in adjuvant chemotherapy, particularly in pediatric cases.
    • To discuss the impact of chemotherapy regimens on survival rates and disease recurrence.

    Main Methods:

    • Review of existing literature and treatment protocols for osteosarcoma.
    • Analysis of survival data from studies utilizing different chemotherapy regimens.

    Related Experiment Videos

  • Discussion of prognostic factors and emerging therapeutic approaches like immunotherapy.

    • Main Results:

    • Adjuvant chemotherapy has significantly improved survival rates compared to amputation alone, with 3-year survival reaching 79% in nonmetastatic cases at M.D. Anderson Hospital.
    • Chemotherapeutic regimens like Compadri-I and Compadri-II show promising results.
    • Despite prolonged survival, disease recurrence remains a concern, indicating that 5-year survival may not equate to a complete cure.

    Conclusions:

    • Innovative postsurgical adjuvant chemotherapy represents a significant advance in treating osteogenic sarcoma.
    • Further research into more intensive therapies and immunotherapy is warranted to improve long-term outcomes and address disease recurrence.
    • Patient immunologic status is a critical factor influencing prognosis and requires further investigation.